The Ethics of Direct-to-Consumer Whole-Body Magnetic Resonance Imaging: Lessons from Direct-to-Consumer Genetic Testing

Abstract: Whole-body MRI (WB-MRI) has been increasingly marketed as a direct-to-consumer (DTC) screening tool, offering asymptomatic individuals a comprehensive scan to detect early disease. However, as with DTC genetic testing, the ethical complications of WB-MRI remain underexamined. Key concerns include informed consent, data privacy, and the unintended consequences of uncertain findings. Unlike clinically indicated screenings, DTC WB-MRI operates outside traditional healthcare frameworks, raising questions about consumer protections, medical oversight, and result disclosure. Similar to genetic testing, DTC WB-MRI can reveal a spectrum of findings: actionable conditions with clear management pathways, indeterminate results requiring further testing, and findings for which no current treatment modalities exist. Without defined pre-test and post-test counseling, individuals may be unprepared for ambiguous results, leading to psychological distress and unnecessary interventions. Additionally, in the absence of robust privacy protections, medical data collected outside of regulated healthcare settings may be subject to unexpected use, transfer, or sale, thus exposing consumers of DTC imaging to unanticipated risks. Unlike clinical imaging, where data security is governed by HIPAA, DTC WB-MRI consumers may have limited control over their medical information, raising concerns about data misuse, profiling, or unintended disclosure. This presentation will describe a structured informed consent framework modeled after genetic testing which includes a stepwise process emphasizing pre-test education to clarify risks and uncertainties and post-test support for informed decision making. Specific consumer protections to safeguard medical privacy in non-clinical settings will be proposed. As DTC imaging expands, policies must evolve to balance patient autonomy with protections against harm.

Keywords: Direct-to-consumer screening, Health data privacy, Shared decision making framework